<DOC>
	<DOCNO>NCT00040872</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Radiation therapy use high-energy x-rays damage tumor cell . Biological therapy use different way stimulate immune system stop cancer cell grow . Combining different type therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine chemotherapy , monoclonal antibody therapy , surgery , peripheral stem cell transplantation , radiation therapy , biological therapy treat patient advanced neuroblastoma .</brief_summary>
	<brief_title>Multiple Therapies Treating Patients With Advanced Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether treatment multimodality therapy comprise dose-intensive induction chemotherapy , monoclonal antibody 3F8 , surgery , myeloablative chemotherapy , autologous syngeneic bone marrow peripheral blood stem cell transplantation , radiotherapy , isotretinoin improve cure rate patient advance neuroblastoma . - Determine whether 2-year progression-free survival ( PFS ) rate improve 70 % patient newly diagnose advanced neuroblastoma treat regimen . - Determine whether 2-year PFS rate improve 40 % patient previously treat advanced neuroblastoma treat regimen . - Determine biologic clinical prognostic factor neuroblastoma may guide future research treatment approach malignancy . OUTLINE : Patients stratify accord following : - Stratum 1 : Patients previously untreated stage IV disease age 1 diagnosis , without N-myc amplification - Stratum 2 : Patients previously treat stage IV disease age 1 diagnosis ; patient previously treat high-risk disease ( e.g. , N-myc amplify stage III IV disease , age 1 diagnosis , without prior treatment ) - Intensive induction therapy ( course 1-5 ) : During course 1 , 2 , 4 , patient receive cyclophosphamide IV 6 hour day 1 2 doxorubicin vincristine IV continuously day 1-3 . Courses repeat every 21 day . During course 3 5 , patient receive etoposide ( VP-16 ) IV 2 hour day 1-3 cisplatin IV 1 hour day 1-4 . Courses repeat every 35 day . Before proceed myeloablative therapy/transplantation , patient stratum 2 must receive minimum 2 course chemotherapy achieve complete response ( CR ) good partial response ( VGPR ) patient must receive minimum 3 course chemotherapy achieve less CR VGPR . Patients undergo tumor resection either diagnosis completion minimum 3 course chemotherapy ( approximately day 63 ) . Treatment monoclonal antibody 3F8 ( MOAB 3F8 ) start completion course 3 intensive induction chemotherapy , preferably surgical resection debulking primary tumor . Patients receive MOAB 3F8 IV 90 minute day 1-5 course 3-5 day 1-5 immediately prior transplantation . - Harvest : Autologous syngeneic bone marrow peripheral blood stem cell ( PBSC ) harvest . Patients undergo PBSC collection receive filgrastim ( G-CSF ) begin 2-3 day prior collection continue end collection . For patient without bone marrow involvement diagnosis , autologous bone marrow PBSC harvest completion 1-2 course induction therapy . For patient bone marrow involvement diagnosis , bone marrow PBSC harvest completion 4 course induction therapy , surgery , completion 1 course MOAB 3F8 , bone marrow remission . If patient 's bone marrow/PBSC collect harvested completion induction therapy hypoplasia persistent tumor , bone marrow/PBSC collect harvest start protocol syngeneic bone marrow/PBSC may use . If neither option available , patient clear marrow course 5 option proceed directly posttransplantation therapy phase , delay transplantation bone marrow clear . - Myeloablative therapy/transplantation : Patients receive thiotepa IV 3 hour day -8 -6 , topotecan IV 30 minute day -8 -4 , carboplatin IV 4 hour day -5 -3 . Patients undergo autologous syngeneic bone marrow transplantation ( BMT ) PBSC transplantation ( PBSCT ) day 0 . - Posttransplantation therapy : Beginning 33 day BMT/PBSCT , patient receive sargramostim ( GM-CSF ) subcutaneously day 1-15 MOAB 3F8 IV within 90 minute ( begin approximately 1 hour initiation GM-CSF infusion ) day 6-15 . Treatment repeat every 28 day 2 course . Beginning 47 day BMT/PBSCT ( day 14 course 1 MOAB 3F8 GM-CSF ) , patient receive localize external beam radiotherapy twice daily 7 consecutive weekday . Beginning 82 day BMT/PBSCT , patient receive alternate course oral VP-16 MOAB 3F8 total 8 course ( total 4 course drug ) . Patients receive oral VP-16 3 time daily day 1-21 , course repeat every 28 day . Patients receive MOAB 3F8 IV within 90 minute day 1-5 , course repeat every 35 day . Beginning 222 day BMT/PBSCT ( 2-3 week completion course 4 oral VP-16 ) , patient receive oral isotretinoin twice daily day 1-14 . Treatment repeat every 28 day 6 course . Beginning day 243 BMT/PBSCT , patient receive MOAB 3F8 IV within 90 minute day 1-5 . Treatment repeat every 28 day 6 course . Treatment continue absence disease progression unacceptable toxicity . Patients follow every 6 month 2 year annually thereafter . PROJECTED ACCRUAL : A maximum 49 patient ( 34 stratum 1 15 stratum 2 ) accrue study within 3 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma 1 follow : Histologic confirmation , include immunohistochemical , ultrastructural , cytogenetic study Elevated urinary catecholamine plus tumor cells/clumps bone marrow Poorrisk disease , define 1 following : Stage IV disease Unresectable primary disease plus Nmyc amplification Infant ( age 1 ) stage IV disease plus Nmyc amplification Previously treat disease allow PATIENT CHARACTERISTICS : Age : 50 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No prior allergy mouse proteins Not pregnant Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Prior murine antibody allow human antimouse antibody ( HAMA ) titer le 1,000 ELISA units/mL Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>regional neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>localize unresectable neuroblastoma</keyword>
</DOC>